Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) EBT Margin (2021 - 2024)

Solid Biosciences (SLDB) has disclosed EBT Margin for 4 consecutive years, with 50728.0% as the latest value for Q4 2024.

  • Quarterly EBT Margin changed N/A to 50728.0% in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 35470.29% through Dec 2024, down 4478590.0% year-over-year, with the annual reading at 83300.0% for FY2025, 11877029.0% down from the prior year.
  • EBT Margin hit 50728.0% in Q4 2024 for Solid Biosciences, up from 40165.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 50728.0% in Q4 2024 to a low of 1315.22% in Q1 2022.
  • Historically, EBT Margin has averaged 16706.72% across 4 years, with a median of 12338.8% in 2022.
  • Biggest five-year swings in EBT Margin: tumbled -80847bps in 2022 and later surged 2639952bps in 2023.
  • Year by year, EBT Margin stood at 509.78% in 2021, then grew by 20bps to 406.69% in 2022, then skyrocketed by 6268bps to 25084.3% in 2023, then soared by 102bps to 50728.0% in 2024.
  • Business Quant data shows EBT Margin for SLDB at 50728.0% in Q4 2024, 40165.85% in Q3 2024, and 28762.5% in Q2 2024.